Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Manu Vatish and Dr Sofia Cerdeira from the Nuffield Department of Women's and Reproductive Health have won a prestigious global award, that recognises teams that collaborate across disciplines and transform healthcare delivery and ultimately patient lives.

Dr Manu Vatish and Dr Sofia Cerdeira from the Nuffield Department of Women's and Reproductive Health have won a prestigious global award, that recognises teams that collaborate across disciplines and transform healthcare delivery and ultimately patient lives.

The annual UNIVANTS of Healthcare Excellence Award was given to credit the working partnership between Roche Diagnostics, Oxford University Hospitals NHS Foundation Trust and Oxford Academic Health Science Network. Their joint expertise resulted in a new test which predicts with much greater accuracy, whether a pregnant woman will develop Pre-eclampsia (PE) within the following seven days.

Pre- eclampsia is a hypertensive disorder of pregnancy, affecting 4-8% of women globally, causing major maternal and fetal morbidity. Roughly half of patients who are admitted to the hospital at risk of PE don’t end up suffering from the condition. Significant resources are used trying to identify PE mothers by measuring blood pressure and proteinuria. This is sub-optimal because these clinical signs have poor diagnostic accuracy, which means clinicians rely on clinical instinct.

“If you don’t have a firm diagnosis, you either incorrectly send someone with Pre-eclampsia home or incorrectly admit someone who doesn’t have Pre-eclampsia,” Vatish said. “Those are both bad outcomes for the professionals involved in their care.” 

Dr Manu Vatish, Dr Sofia Cerdeira and Dr Tim James (Department of Clinical Biochemistry, Oxford University Hospitals NHS Foundation Trust) worked extensively around the potential use of laboratory tests that could offer clinicians reassurance of their PE diagnosis while avoiding hospitalization of patients who won’t develop the condition. They found significant opportunity in two angiogenic biomarkers: Placental Growth Factor (PlGF), and its receptor, Soluble Flt-1. These biomarkers showed a very powerful negative predictive value, meaning they were a reliable indicator of patients who were not likely to develop PE.

The test was developed by Roche Diagnostics and a clinical trial was run at the John Radcliffe Hospital (Oxford University Hospitals NHS Foundation Trust). Following improved patient outcomes, the Oxford Academic Health Science Network launched the test to other maternity units across the UK. It has been well-received by patients, who are often unnecessarily frightened when PE is explained to them during prenatal visits. Hospitalization can be a frustrating experience for patients who ultimately have their baby without issue.

This high profile award attracted 300 applications from 97 countries. It is a fantastic acknowledgment of how shared expertise across disciplines, including the core laboratory, can reshape care pathways and ultimately achieve better outcomes for patients, clinicians, payers and entire health systems. 


Latest news

New Endometriosis podcast launched: "Unheard of"

Listen now to the first episode ‘Unheard of – The hidden voice of Endometriosis.’ A bold new podcast series co-hosted by DPhil students Danielle Perro and Magda Mareckova, it seeks answers to the biggest questions posed by the Endometriosis community.

Blood pressure lowering drugs not found to increase risk of cancer

A world leading study involving over 260,000 participants has sought to resolve the long debated issue about whether using antihypertensive medication heightens the chance of developing cancer.

First patient dose in HPV clinical trial

Vaccitech Ltd, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the dosing of the first patient as part of the HPV001 clinical study.

Similar stories

Best Oral Presentations

General Maternal & Fetal Health

The Nuffield Department of Women's & Reproductive Health is celebrating two wins at the recent annual academic meeting of the Royal College of Obstetricians and Gynaecologists, held on 27th February 2020.

How do unborn babies and mothers communicate via the placenta?

Maternal & Fetal Health

DPhil student Neva Kandzija wins an Oxford Sparks competition to have her Placenta research transformed into a two minute animation film for free.

100 000 babies screened for increased type 1 diabetes risk in the INGR1D Study

Maternal & Fetal Health

Celebrating a major milestone for one of Europe’s biggest type 1 diabetes research cooperations: The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) has successfully screened 100,000 newborns across Europe (including over 7500 newborns in the Thames Valley) for an increased genetic risk of developing type 1 diabetes.

Innovative exosome research aims to create new technology that will predict Pre-eclampsia

Maternal & Fetal Health

JVCKENWOOD launches joint research with Oxford University and Sysmex R&D Center Europe GmbH to establish a system for predicting the onset of Pre-eclampsia using exosomes.

Pregnant women to help test vaccine against childhood virus

Maternal & Fetal Health

Pregnant women receiving antenatal care in the Women’s Centre at Oxford’s John Radcliffe Hospital may be asked to take part in a world-first clinical trial to find a vaccine against a common and potentially serious viral infection in babies.

Honour for George Institute UK Executive Director

General Global Health Maternal & Fetal Health

Executive Director of The George Institute, UK, Professor Terry Dwyer has been awarded an honorary doctorate by Trinity College Dublin for his extensive work in child health.